SyneuRx is currently conducting clinical development of two COVID-19 treatments— Pentarlandir® in oral capsule form and Airnecflu® in an inhaled form. Pentarlandir® began US Phase 2 clinical trial following FDA IND approval in Q2 2021 (click here for trial information: NCT04911777). The Phase 3 study is expected to be launched in 2022 as a global multi-center clinical trial. First-in-human study for Airnecflu® is expected to launch in H1 2022.